NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of dependencies and addictions, and in particular NFL-101, its drug candidate for smoking cessation, announces its participation in the 16th annual congress of the Company Francophone de Tabacologie (CSFT), November 24 and 25 in Dijon.
The CSFT 2022 is the flagship event dominating the world of Tobacco in France and in French-speaking countries and of all the actors who revolve around it. More than 350 participants are expected. On this occasion, NFL Biosciences is exhibiting, which will allow it to meet tobacco specialists and healthcare personnel involved in the fight against smoking in order to present to them its drug candidate, NFL-101, with its two ongoing clinical studies ( CESTO II and PRECESTO), and to discuss with the pharmaceutical companies present.
